API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Company launched USFDA approved Venlafaxine Hydrochloride-Generic, an selective serotonin and norepinephrine reuptake inhibitors for the treatment of major depressive disorder, generalized anxiety disorder, panic disorder, and social phobia.
Lead Product(s): Venlafaxine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Venlafaxine Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021